| Identification | Back Directory | [Name]
1A-116 | [CAS]
1430208-73-3 | [Synonyms]
1A-116
1A-116; 1A 116; 1A116;1430208-73-3
Guanidine, N-(3,5-dimethylphenyl)-N'-[2-(trifluoromethyl)phenyl]-
TIAM1,inhibit,1A 116,Ras,Rho GTPases,EGF,Apoptosis,1A-116,circadian rhythms,1A116,Inhibitor | [Molecular Formula]
C16H16F3N3 | [MOL File]
1430208-73-3.mol | [Molecular Weight]
307.31 |
| Chemical Properties | Back Directory | [Boiling point ]
357.5±52.0 °C(Predicted) | [density ]
1.22±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (325.40 mM);Water : < 0.1 mg/mL (insoluble) | [form ]
Solid | [pka]
9.78±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
A1-116 is a novel specific Rac1 inhibitor. | [in vivo]
1A-116 (3 mg/kg; i.v.; once a day for 21 days) demonstrates a high antimetastatic activity with about 60% formation reduction of total metastatic lung colonies in vivo and shows no apparent toxicity[1].
?
1A-116 (20 mg/kg; i.p.; once a day, 73 days for ZT12, 68 days for ZT3) increases survival time when treated at ZT12 compare to ZT3 in tumor-bearing mice. (ZT: Zeitgeber time 12 (ZT12) defined as the time of lights off (local time 7 p.m.) and ZT0 defined as lights on (local time 7 a.m.))[2].
?
1A-116 shows good oral availability[3]. | Animal Model: | Female BALB/c inbred mice (8 to 10-week-old; average 20 g)[1] | | Dosage: | 3 mg/kg | | Administration: | Intravenous injection; once a day for 21 days. | | Result: | Demonstrated a high antimetastatic activity. |
| Animal Model: | Male NIH Swiss foxN1(?/?) nude mice (2-month-old; GBM model)[2]. | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection (at ZT3, ZT12); once a day, 73 days for ZT12, 68 days for ZT3. | | Result: | Increased survival time when treated at ZT12 compared to ZT3 in tumor-bearing mice. |
| [storage]
Store at -20°C |
|
|